InvestorsHub Logo
Followers 4
Posts 1195
Boards Moderated 0
Alias Born 10/03/2015

Re: jondoeuk post# 119

Saturday, 05/14/2022 9:26:23 PM

Saturday, May 14, 2022 9:26:23 PM

Post# of 301
Cell therapy will be the backbone of therapies to treat solid tumors.

Roche is testing a mechanism that blocks TIGIT, a receptor capable of shrouding cancer cells from the immune system. Its drug, tiragolumab, binds to the receptor, preventing its deception. Roche added the new drug to its blockbuster medicine Tecentriq in patients with a form of lung cancer.

But during an interim analysis, Roche's regimen failed to meet the study's two key goals. It didn't have a statistically significant impact on the length of time before patients worsened — a measure known as progression-free survival. And it didn't improve overall survival.

https://www.investors.com/news/technology/biotech-stocks-arcus-and-others-hammered-on-roche-flop-in-lung-cancer/?src=A00220
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DTIL News